Compare Gold Fields Limited (GFI) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Gilead Sciences, Inc. — how do they compare? Gold Fields Limited trades at $37.41 (market cap $31.87B), while Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 5.7× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (6%). Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and Gilead Sciences, Inc. for 111 Days on average.
| GFI | GILD | |
|---|---|---|
Market Cap | $31.87B | $182.40B |
Volume | 4,169,651 | 4,469,821 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $155.80 |
52-Week Low | $31.25 | $116.74 |
Typical Hold Time | 49 Days | 111 Days |
Enterprise Value | $32.47B | $205.46B |
Dividend Yield | 6% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.05, down 3.1% amid market reaction to its rejected $27 billion bid for Northern Star. The stock shows a bearish technical signal with key support at $34-$35, while fundamentals remain strong with a 40.76% net margin and low P/E of 7.3. Recent earnings saw mixed results, with one beat and three misses against expectations.
The outlook is balanced: robust cash flow and high profitability support upside toward the $52.75 analyst target, but acquisition uncertainty and technical weakness pose near-term risks. Investor sentiment is cautious pending clarity on M&A strategy and capital allocation.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
